About

Breaking Ground.jpg

We believe in a collaborative approach in development, speed and flexibility in operations, and high quality in everything we do.

Evergreen Theragnostics

Evergreen Theragnostics is a radiopharmaceutical company focused on improving the available options for cancer patients through radiopharmaceuticals. We are engaged in three core areas:

  • CDMO: Contract Development and Manufacturing of radio pharmaceuticals

  • Products: Development and commercialization of radiopharmaceutical products (incl. Ga-68 DOTATOC)

  • Discovery: Discovery and development of novel radiopharmaceuticals to address unmet clinical needs.

The company was founded in 2019 and is headquartered in Springfield, NJ.

 

Management Team

  • James Cook

    CEO & CO-FOUNDER

  • Dr. Serge Lyashchenko

    SENIOR ADVISOR & CO-FOUNDER

  • Dr. Thomas Reiner

    CHIEF SCIENTIFIC OFFICER

  • Eric Luthi

    CHIEF COMMERCIAL OFFICER

  • Alison Tillbrook

    HEAD OF HUMAN RESOURCES

  • Alex Agnoletto

    CHIEF FINANCIAL OFFICER

  • Kevin Staton

    VP, CDMO PROJECT MANAGEMENT

  • Kyle Powell

    HEAD OF QUALITY

  • Dr. Kyle Hoffmann

    HEAD OF FACILITY OPERATIONS & RADIATION SAFETY OFFICER

  • Shruti Jambudi

    REGULATORY AFFAIRS MANAGER

  • Dipesh Patel

    GENERAL COUNSEL

Board of Directors

  • Gérard Ber

  • Enrico de Maria

  • James Cook

  • Serge Lyashchenko

  • Sharon Roded

Advisory Board

  • Dr. Jason Lewis

    ADVISOR

  • Heinz Mäusli

    ADVISOR

—

Join our team.